DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Quillichew Er is a drug marketed by Nextwave Pharms and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-eight patent family members in fourteen countries.
The generic ingredient in QUILLICHEW ER is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
A generic version of QUILLICHEW ER was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
Summary for QUILLICHEW ER
|Finished Product Suppliers / Packagers:||2|
|Raw Ingredient (Bulk) Api Vendors:||50|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for QUILLICHEW ER|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for QUILLICHEW ER|
|What excipients (inactive ingredients) are in QUILLICHEW ER?||QUILLICHEW ER excipients list|
|DailyMed Link:||QUILLICHEW ER at DailyMed|
Recent Clinical Trials for QUILLICHEW ER
Identify potential brand extensions & 505(b)(2) entrants
Pharmacology for QUILLICHEW ER
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2012112140||⤷ Free Forever Trial|
|South Korea||101495146||⤷ Free Forever Trial|
|Spain||2717469||⤷ Free Forever Trial|
|Spain||2378573||⤷ Free Forever Trial|
|Australia||2007227569||⤷ Free Forever Trial|
|Japan||5479086||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|